sphingosine-1-phosphate and Influenza--Human

sphingosine-1-phosphate has been researched along with Influenza--Human* in 3 studies

Reviews

2 review(s) available for sphingosine-1-phosphate and Influenza--Human

ArticleYear
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.
    The Journal of clinical investigation, 2015, Volume: 125, Issue:4

    Membrane sphingolipids are metabolized to sphingosine-1-phosphate (S1P), a bioactive lipid mediator that regulates many processes in vertebrate development, physiology, and pathology. Once exported out of cells by cell-specific transporters, chaperone-bound S1P is spatially compartmentalized in the circulatory system. Extracellular S1P interacts with five GPCRs that are widely expressed and transduce intracellular signals to regulate cellular behavior, such as migration, adhesion, survival, and proliferation. While many organ systems are affected, S1P signaling is essential for vascular development, neurogenesis, and lymphocyte trafficking. Recently, a pharmacological S1P receptor antagonist has won approval to control autoimmune neuroinflammation in multiple sclerosis. The availability of pharmacological tools as well as mouse genetic models has revealed several physiological actions of S1P and begun to shed light on its pathological roles. The unique mode of signaling of this lysophospholipid mediator is providing novel opportunities for therapeutic intervention, with possibilities to target not only GPCRs but also transporters, metabolic enzymes, and chaperones.

    Topics: Acute Lung Injury; Anemia, Sickle Cell; Animals; Autoimmune Diseases; Cardiovascular Diseases; Cell Physiological Phenomena; Disease Models, Animal; Fingolimod Hydrochloride; Hematopoietic Stem Cell Mobilization; Humans; Influenza, Human; Lysophospholipids; Membrane Lipids; Mice; Multiple Sclerosis; Neoplasms; Neovascularization, Physiologic; Neurogenesis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine

2015
Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule.
    Current topics in microbiology and immunology, 2014, Volume: 378

    Cytokine storm defines a dysregulation of and an excessively exaggerated immune response most often accompanying selected viral infections and several autoimmune diseases. Newly emerging and re-emerging infections of the respiratory tract, especially influenza, SARS, and hantavirus post considerable medical problems. Their morbidities and mortalities are often a direct result of cytokine storm. This chapter visits primarily influenza virus infection and resultant cytokine storm. It provides the compelling evidence that illuminates cytokine storm in influenza pathogenesis and the clear findings that cytokine storm is chemically tractable by therapy directed toward sphingosine-1-phosphate receptor (S1PR) modulation, specifically S1P1R agonist therapy. The mechanism(s) of how S1P1R signaling works and the pathways involved are subjects of this review.

    Topics: Animals; Cytokines; Humans; Influenza, Human; Lysophospholipids; Orthomyxoviridae; Sphingosine

2014

Other Studies

1 other study(ies) available for sphingosine-1-phosphate and Influenza--Human

ArticleYear
Analyzing Opposing Interactions Between Sphingosine 1-Phosphate Lyase and Influenza A Virus.
    DNA and cell biology, 2022, Volume: 41, Issue:4

    Sphingosine 1-phosphate lyase (SPL) is a critical component of sphingosine 1-phosphate (S1P) metabolism. SPL has been associated with several crucial cellular functions due to its role in S1P metabolism, but its role in viral infections is poorly understood. Studies show that SPL has an antiviral function against influenza A virus (IAV) by interacting with IKKÉ›, promoting the type I interferon (IFN) innate immune response to IAV infection. However, a more recent study has revealed that IAV NS1 protein hampers this by triggering ubiquitination and subsequent degradation of SPL, which reduces the type I IFN innate immune response. In this study, we describe SPL, the type I IFN response, and known interactions between SPL and IAV.

    Topics: Host-Pathogen Interactions; Humans; Immunity, Innate; Influenza A virus; Influenza, Human; Lysophospholipids; Sphingosine

2022